胸部双能CT评估糖皮质激素对重症COVID-19患者肺功能的影响
本研究为单中心前瞻性观察研究,纳入瑞典乌普萨拉大学医院ICU接受双能CT检查的重症COVID-19患者60例,其中43例使用糖皮质激素。通过双能CT分析全肺及通气低下区域的肺血容量分布(作为HPV的替代指标)和总肺重量(作为肺水肿指标)。结果显示,未使用激素组非灌注区更广泛(19% vs 13%,p<0.01),通气低下区肺血容量分布更不均匀(峰度1.91 vs 2.69,p<0.01),提示HPV保留;使用激素组肺重量更低(953 g vs 1140 g,p=0.01),且肺泡-动脉氧分压差从入ICU时322±106 mmHg降至DECT时267±99 mmHg(p=0.04)。作者认为激素可能损害HPV并减轻肺水肿。
要点
- 重症COVID-19未用激素者非灌注区更广泛(19% vs 13%,p<0.01),提示HPV保留;用激素者可能HPV受损。
- 用激素者通气低下区肺血容量分布更均匀(峰度1.91 vs 2.69,p<0.01),未用激素者分布更不均匀。
- 用激素者总肺重量更低(953 g vs 1140 g,p=0.01),提示肺水肿减轻。
- 用激素者肺泡-动脉氧分压差从入ICU时322±106 mmHg降至DECT时267±99 mmHg(p=0.04)。
- 作者认为激素可能损害HPV并减轻肺水肿,与既往其他疾病的发现一致。
适用人群与场景
- 单中心前瞻性观察研究,纳入瑞典乌普萨拉大学医院ICU接受双能CT检查的重症COVID-19患者60例,其中43例使用糖皮质激素。
研究设计与关键结果
- 研究类型:单中心前瞻性观察研究,样本量60例,其中43例使用糖皮质激素。
- 主要终点:未使用激素组非灌注区更广泛(19% vs 13%,p<0.01),通气低下区肺血容量分布峰度更低(1.91 vs 2.69,p<0.01),提示HPV保留;使用激素组肺重量更低(953 g vs 1140 g,p=0.01)。
- 次要终点:使用激素组肺泡-动脉氧分压差从入ICU时322±106 mmHg降至DECT时267±99 mmHg(p=0.04)。
证据类型、等级与局限
- 证据类型:单中心前瞻性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,重症COVID-19中使用糖皮质激素可能损害HPV并减轻肺水肿,与既往其他疾病的发现一致。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Steroids have been shown to reduce inflammation, hypoxic pulmonary vasoconstriction (HPV) and lung edema. Based on evidence from clinical trials, steroids are widely used in severe COVID-19. However, the effects of steroids on pulmonary gas volume and blood volume in this group of patients are unexplored.
OBJECTIVE: Profiting by dual-energy computed tomography (DECT), we investigated the relationship between the use of steroids in COVID-19 and distribution of blood volume as an index of impaired HPV. We also investigated whether the use of steroids influences lung weight, as index of lung edema, and how it affects gas distribution.
METHODS: Severe COVID-19 patients included in a single-center prospective observational study at the intensive care unit at Uppsala University Hospital who had undergone DECT were enrolled in the current study. Patients' cohort was divided into two groups depending on the administration of steroids. From each patient's DECT, 20 gas volume maps and the corresponding 20 blood volume maps, evenly distributed along the cranial-caudal axis, were analyzed. As a proxy for HPV, pulmonary blood volume distribution was analyzed in both the whole lung and the hypoinflated areas. Total lung weight, index of lung edema, was estimated.
RESULTS: Sixty patients were analyzed, whereof 43 received steroids. Patients not exposed to steroids showed a more extensive non-perfused area (19% vs 13%, p < 0.01) and less homogeneous pulmonary blood volume of hypoinflated areas (kurtosis: 1.91 vs 2.69, p < 0.01), suggesting a preserved HPV compared to patients treated with steroids. Moreover, patients exposed to steroids showed a significantly lower lung weight (953 gr vs 1140 gr, p = 0.01). A reduction in alveolar-arterial difference of oxygen followed the treatment with steroids (322 ± 106 mmHg at admission vs 267 ± 99 mmHg at DECT, p = 0.04).
CONCLUSIONS: The use of steroids might cause impaired HPV and might reduce lung edema in severe COVID-19. This is consistent with previous findings in other diseases. Moreover, a reduced lung weight, as index of decreased lung edema, and a more homogeneous distribution of gas within the lung were shown in patients treated with steroids.
TRIAL REGISTRATION: Clinical Trials ID: NCT04316884, Registered March 13, 2020.
参考来源
- Perchiazzi G, Larina A, Hansen T, et al. Chest dual-energy CT to assess the effects of steroids on lung function in severe COVID-19 patients. Crit Care. 2022. PMID: 36284360. doi:10.1186/s13054-022-04200-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。